Compare VITL & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VITL | CTNM |
|---|---|---|
| Founded | 2007 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 557.9M | 550.7M |
| IPO Year | 2020 | 2024 |
| Metric | VITL | CTNM |
|---|---|---|
| Price | $9.74 | $14.82 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 4 |
| Target Price | ★ $32.00 | $19.00 |
| AVG Volume (30 Days) | ★ 1.2M | 500.0K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.03 | 0.46 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $759,444,000.00 | N/A |
| Revenue This Year | $19.72 | N/A |
| Revenue Next Year | $17.02 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 25.26 | N/A |
| 52 Week Low | $7.95 | $8.60 |
| 52 Week High | $49.04 | $17.79 |
| Indicator | VITL | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 33.60 | 42.13 |
| Support Level | $7.95 | $13.65 |
| Resistance Level | $10.60 | $15.36 |
| Average True Range (ATR) | 0.47 | 0.91 |
| MACD | -0.04 | -0.25 |
| Stochastic Oscillator | 2.39 | 2.35 |
Vital Farms Inc is an ethical food company. The company retails pasture-raised eggs and butter. Its products include Pasture-Raised Eggs and Pasture-Raised Butter & Ghee. The company's purpose is rooted in a commitment to Conscious Capitalism, which prioritizes the long-term benefits of its stakeholders (farmers and suppliers, customers and consumers, communities and the environment, employees, and stockholders).
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.